Johnson Dermatology

Fort Smith, Arkansas 72916-6103

1 studies enrolling now · 35 studies all time

What they study most

Acne, Acne Vulgaris, Alopecia Areata, Atopic Dermatitis, Cardiovascular Diseases, Chronic Spontaneous Urticaria, Common Warts (Verruca Vulgaris), Eczema, Hidradenitis Suppurativa, Human Papilloma Virus, Obesity, Papulopustular Rosacea

Studies at this site

• A Study of Zasocitinib in Adults With Hidradenitis Suppurativa — Recruiting now
• Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis — Running, not enrolling
• A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis — Running, not enrolling
• A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis — Running, not enrolling
• A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet) — Running, not enrolling
• Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight — Completed
• Comparative Effectiveness Study of Spironolactone Versus Doxycycline for Acne — Running, not enrolling
• A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) — Running, not enrolling
• A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis — Completed
• A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata — Completed
• A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC — Running, not enrolling
• A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis — Stopped early
• A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) — Completed
• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
• Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata — Running, not enrolling
• Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis — Running, not enrolling
• Candin for the Treatment of Common Warts — Completed
• Light Treatment Effectiveness (LITE) Study — Completed
• Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea — Completed
• A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis — Stopped early
• Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2) — Completed
• An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis — Completed
• A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) — Completed
• Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1) — Completed
• A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis — Stopped early
• A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis — Completed
• Mirvaso in Use Study — Completed
• AGN-242428 in the Treatment of Plaque Psoriasis — Stopped early
• Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis — Completed
• Candin Safety & Efficacy Study for the Treatment of Warts — Completed
• A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26) — Completed
• An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris — Completed
• A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis — Completed
• Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema — Completed
• Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris) — Completed